The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Cannabinoid CB2 Receptors Modulate Microglia Function and Amyloid Dynamics in a Mouse Model of Alzheimer’s Disease
Abstract
The distribution and roles of the cannabinoid CB 2 receptor in the CNS are still a matter of debate. Recent data suggest that, in addition to its presence in microglial cells, the CB 2 receptor may be also expressed at low levels, yet biologically relevant, in other cell types such as neurons. It is accepted that the expression of CB 2 receptors in the CNS is low under physiological conditions and is significantly elevated in chronic neuroinflammatory states associated with neurodegenerative diseases such as Alzheimer’s disease. By using a novel mouse model (CB 2EGFP/f/f), we studied the distribution of cannabinoid CB 2 receptors in the 5xFAD mouse model of Alzheimer’s disease (by generating 5xFAD/CB 2EGFP/f/f mice) and explored the roles of CB 2 receptors in microglial function. We used a novel selective and brain penetrant CB 2 receptor agonist (RO6866945) as well as mice lacking the CB 2 receptor (5xFAD/CB 2−/−) for these studies. We found that CB 2 receptors are expressed in dystrophic neurite-associated microglia and that their modulation modifies the number and activity of microglial cells as well as the metabolism of the insoluble form of the amyloid peptide. These results support microglial CB 2 receptors as potential targets for the development of amyloid-modulating therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Under basal conditions, GFP expression, marking CB2 activity, was detected in peripheral tissues but was minimal in the CNS, consistent with previous GFP-CB2 models (López et al., 2018; Ruiz De Martín Esteban et al., 2022).”
From Novel floxed cannabinoid receptor 2 mouse line combines knockout capability with dual fluorescent reporters (2025) · cites this paper as Ruiz De Martín Esteban et al., 2022
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530
The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
Disease-Associated Microglia: A Universal Immune Sensor of Neurodegeneration
Deczkowska, A., Keren-Shaul, H., Weiner, A., Colonna, M., Schwartz, M., & Amit, I. (2018) · Cell · doi:10.1016/j.cell.2018.05.003 · Cited by 1,474 · cited 1×
“When an alteration takes place in the brain parenchyma, these cells become “activated”, and shape their phenotype to cope with this alteration by modifying their structural properties, gene expression profile, ability to produce cytokines and other cell mediators, and phagocytic activity (becoming “damage-associated m…”
BackgroundThe endocannabinoid system and the brain.
Mechoulam, R., & Parker, L. A. (2013) · Annual Review of Psychology · doi:10.1146/annurev-psych-113011-143739 · Cited by 1,090 · cited 1×
“…of cells and tissues, the distribution of CB2 receptors is restricted to specific types of cells (B-lymphocytes, natural killer cells, monocytes, etc) and tissues (spleen, Peyer’s patches) and its brain expression is low under physiological conditions (for review, see Mechoulam and Parker, 2013).”
BackgroundSpangenberg, E., Severson, P. L., Hohsfield, L. A., Crapser, J., Zhang, J., Burton, E. A., Zhang, Y., Spevak, W., Lin, J., Phan, N. Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11674-z · Cited by 939
TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques
Wang, Y., Ulland, T. K., Ulrich, J. D., Song, W., Tzaferis, J. A., Hole, J. T., Yuan, P., Mahan, T. E., Shi, Y., Gilfillan, S., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151948 · Cited by 840 · cited 1×
“A similar effect has been described in TREM2-lacking mice, suggesting an impairment in microglial function (Wang et al., 2016).”
BackgroundMicroglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques
Condello, C., Yuan, P., Schain, A., & Grutzendler, J. (2015) · Nature Communications · doi:10.1038/ncomms7176 · Cited by 718
Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer’s disease.
Forner, S., Kawauchi, S., Balderrama-Gutierrez, G., Kramár, E. A., Matheos, D. P., Phan, J., Javonillo, D. I., Tran, K. M., Hingco, E., da Cunha, C., et al. (2021) · Scientific Data · doi:10.1038/s41597-021-01054-y · Cited by 501
Role of toll-like receptor signalling in A uptake and clearance
Tahara, K., Kim, H.-D., Jin, J.-J., Maxwell, J. A., Li, L., & Fukuchi, K.-I. (2006) · Brain · doi:10.1093/brain/awl249 · Cited by 493 · cited 1×
“Furthermore, the significant decrease in the phagocytic activity of CB2-lacking microglia we herein report may be also associated to the loss of TLR function, as these receptors are well-known for their critical role in the uptake and clearance of amyloid by these cells (Tahara et al., 2006).”
BackgroundZhang, H.-Y., Gao, M., Liu, Q.-R., Bi, G.-H., Li, X., Yang, H.-J., Gardner, E. L., Wu, J., & Xi, Z.-X. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413210111 · Cited by 334
The identity and function of microglia in neurodegeneration
Song, W. M., & Colonna, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0212-1 · Cited by 308
Benito, C., Romero, J. P., Tolón, R. M., Clemente, D., Docagne, F., Hillard, C. J., Guaza, C., & Romero, J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4814-06.2007 · Cited by 256
Self-citationCasali, B. T., MacPherson, K. P., Reed-Geaghan, E. G., & Landreth, G. E. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104956 · Cited by 186
Research works printed but not linked: 25
- Aso, 2016, Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine, J. Alzheimers Dis., 51, 489, 10.3233/JAD-150913 · DOI
- Benito, The Endocannabinoid System and Alzheimer's Disease, Mol. Neurobiol., 36, 75, 10.1007/s12035-007-8006-8 · DOI
- Benito, 2003, Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains, J. Neurosci., 23, 11136, 10.1523/jneurosci.23-35-11136.2003 · DOI · Paper page
- Cabañero, 2020, Protective Role of Neuronal and Lymphoid Cannabinoid CB2 Receptors in Neuropathic Pain, Elife, 9, e55582, 10.7554/eLife.55582 · DOI
- Espejo-Porras, 2019, Targeting Glial Cannabinoid CB2 Receptors to Delay the Progression of the Pathological Phenotype in TDP-43 (A315T) Transgenic Mice, a Model of Amyotrophic Lateral Sclerosis, Br. J. Pharmacol., 176, 1585, 10.1111/bph.14216 · DOI
- Galán-Ganga, 2021, Cannabinoid Receptor CB2 Ablation Protects against TAU Induced Neurodegeneration, Acta Neuropathol. Commun., 9, 90, 10.1186/s40478-021-01196-5 · DOI
- He, 2021, β-Caryophyllene, an FDA-Approved Food Additive, Inhibits Methamphetamine-Taking and Methamphetamine-Seeking Behaviors Possibly via CB2 and Non-CB2 Receptor Mechanisms, Front. Pharmacol., 12, 722476, 10.3389/fphar.2021.722476 · DOI
- Komorowska-Müller, 2020, CB2 Receptor in Microglia: The Guardian of Self-Control, Int. J. Mol. Sci., 22, 19, 10.3390/ijms22010019 · DOI · Paper page
- Koppel, 2014, CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimer's Disease, Mol. Med., 20, 29, 10.2119/molmed.2013.00140.revised · DOI
- López, 2018, Cannabinoid CB2 Receptors in the Mouse Brain: Relevance for Alzheimer's Disease, J. Neuroinflammation, 15, 158, 10.1186/s12974-018-1174-9 · DOI · Paper page
- Maresz, 2005, Modulation of the Cannabinoid CB2 Receptor in Microglial Cells in Response to Inflammatory Stimuli, J. Neurochem., 95, 437, 10.1111/j.1471-4159.2005.03380.x · DOI · Paper page
- Mecha, 2016, Microglia Activation States and Cannabinoid System: Therapeutic Implications, Pharmacol. Ther., 166, 40, 10.1016/j.pharmthera.2016.06.011 · DOI · Paper page
- Nimmerjahn, 2005, Resting Microglial Cells Are Highly Dynamic Surveillants of Brain Parenchyma In Vivo, Science, 308, 1314, 10.1126/science.1110647 · DOI · Paper page
- Onaivi, 2008, Functional Expression of Brain Neuronal CB2 Cannabinoid Receptors are Involved in the Effects of Drugs of Abuse and in Depression, Ann. N. Y. Acad. Sci., 1139, 434, 10.1196/annals.1432.036 · DOI · Paper page
- Ouali Alami, 2018, NF-κB Activation in Astrocytes Drives a Stage-Specific Beneficial Neuroimmunological Response in ALS, EMBO J., 37, e98697, 10.15252/embj.201798697 · DOI
- Pertwee, 2010, International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: beyond CB₁ and CB₂, Pharmacol. Rev., 62, 588, 10.1124/pr.110.003004 · DOI · Paper page
- Puente, 2019, High-Resolution Immunoelectron Microscopy Techniques for Revealing Distinct Subcellular Type 1 Cannabinoid Receptor Domains in Brain, Bio Protoc., 9, e3145, 10.21769/BioProtoc.3145 · DOI
- Querfurth, 2010, Alzheimer's Disease, N. Engl. J. Med., 362, 329, 10.1056/NEJMra0909142 · DOI · Paper page
- Reusch, 2022, Cannabinoid Receptor 2 Is Necessary to Induce Toll-like Receptor-Mediated Microglial Activation, Glia, 70, 71, 10.1002/glia.24089 · DOI
- Rodríguez-Cueto, 2021, Inactivation of the CB 2 Receptor Accelerated the Neuropathological Deterioration in TDP‐43 Transgenic Mice, a Model of Amyotrophic Lateral Sclerosis, Brain Pathol., 31, e12972, 10.1111/bpa.12972 · DOI
- Sarott, 2020, Development of High-Specificity Fluorescent Probes to Enable Cannabinoid Type 2 Receptor Studies in Living Cells, J. Am. Chem. Soc., 142, 16953, 10.1021/jacs.0c05587 · DOI
- Savonenko, 2015, Cannabinoid CB2 Receptors in a Mouse Model of Aβ Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation, PLoS One, 10, e0129618, 10.1371/journal.pone.0129618 · DOI
- Schmöle, 2015, Cannabinoid Receptor 2 Deficiency Results in Reduced Neuroinflammation in an Alzheimer's Disease Mouse Model, Neurobiol. Aging, 36, 710, 10.1016/j.neurobiolaging.2014.09.019 · DOI
- Schmöle, 2018, Cannabinoid Receptor 2-Deficiency Ameliorates Disease Symptoms in a Mouse Model with Alzheimer's Disease-Like Pathology, J. Alzheimers. Dis., 64, 379, 10.3233/JAD-180230 · DOI
- Wu, 2017, Activation of CB2 Receptor System Restores Cognitive Capacity and Hippocampal Sox2 Expression in a Transgenic Mouse Model of Alzheimer's Disease, Eur. J. Pharmacol., 811, 12, 10.1016/j.ejphar.2017.05.044 · DOI
Cited by
Kamila, P., Kar, K., Chowdhury, S., Chakraborty, P., Dutta, R., S, S., Singh S, A., & Prajapati, B. G. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.05.005 · Cited by 90
Laloli, K. J., Rentsch, P., Stayte, S., & Vissel, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1682979 · Cited by 3
Metadata
- Authors
- Ruiz de Martín Esteban, S., Benito-Cuesta, I., Terradillos, I., Martínez-Relimpio, A. M., Arnanz, M. A., Ruiz-Pérez, G., Korn, C., Raposo, C., Sarott, R. C., Westphal, M. V., Elezgarai, I., Carreira, E. M., Hillard, C. J., Grether, U., Grandes, P., Grande, M. T., & Romero, J.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2022-04-27
- Volume
- 13
- ISSN
- 1663-9812
- Cited by
- 45
- References
- 13
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.